Stokes Jeffrey
Division of Allergy, Immunology and Pulmonary Medicine, Department of Pediatrics, Washington University in St. Louis School of Medicine, St. Louis, MO, United States.
Front Med (Lausanne). 2017 Sep 21;4:152. doi: 10.3389/fmed.2017.00152. eCollection 2017.
Immunoglobulin E (IgE) plays a key role in the pathogenesis of many allergic diseases. Thus, IgE-mediated immunologic pathways are an attractive target for intervention in allergic diseases. Omalizumab is a recombinant humanized monoclonal antibody that binds IgE and has been used treat allergic asthma for over a decade. Currently, omalizumab is approved for the treatment of both allergic asthma and chronic spontaneous urticaria. Since IgE plays a critical role in other allergic diseases, anti-IgE therapy has been evaluated in other allergic diseases in small clinical trials and case reports. Omalizumab has demonstrated efficacy in treating allergic rhinitis, atopic dermatitis, physical urticarias, mast cell disorders, food allergy, and other allergic diseases. In addition, the use of omalizumab with conventional allergen immunotherapy improves both safety and effectiveness.
免疫球蛋白E（IgE）在许多过敏性疾病的发病机制中起关键作用。因此，IgE介导的免疫途径是干预过敏性疾病的一个有吸引力的靶点。奥马珠单抗是一种重组人源化单克隆抗体，可与IgE结合，已用于治疗过敏性哮喘十多年。目前，奥马珠单抗已被批准用于治疗过敏性哮喘和慢性自发性荨麻疹。由于IgE在其他过敏性疾病中起关键作用，抗IgE疗法已在其他过敏性疾病的小型临床试验和病例报告中进行了评估。奥马珠单抗已证明在治疗过敏性鼻炎、特应性皮炎、物理性荨麻疹、肥大细胞疾病、食物过敏和其他过敏性疾病方面有效。此外，将奥马珠单抗与传统的过敏原免疫疗法联合使用可提高安全性和有效性。
